KOD Quote, Financials, Valuation and Earnings

Catalyst Pharmaceuticals, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of 34.53%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2%.

Kodiak Sciences, Inc. has a consensus price target of $56.33, signalling upside risk potential of 38.65%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 37.71%. Given that Kodiak Sciences, Inc. has higher upside potential than Catalyst Pharmaceuticals, Inc., analysts believe Kodiak Sciences, Inc. is more attractive than Catalyst Pharmaceuticals, Inc..

Kodiak Sciences, Inc. has a beta of 2.394, which suggesting that the stock is 139.374% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.667, suggesting its less volatile than the S&P 500 by 33.264%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $152.6M. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.7M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 5.30x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of 34.4%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Eli Lilly & Co.'s return on equity of 104.39%.

Kodiak Sciences, Inc. has a consensus price target of $56.33, signalling upside risk potential of 38.65%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 29.25%. Given that Kodiak Sciences, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Kodiak Sciences, Inc. is more attractive than Eli Lilly & Co..

Kodiak Sciences, Inc. has a beta of 2.394, which suggesting that the stock is 139.374% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.68% to investors and pays a quarterly dividend of $1.73 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 12.82x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of -18.24%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53%.

Kodiak Sciences, Inc. has a consensus price target of $56.33, signalling upside risk potential of 38.65%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $668.57 which suggests that it could grow by 22.25%. Given that Kodiak Sciences, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Kodiak Sciences, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Kodiak Sciences, Inc. has a beta of 2.394, which suggesting that the stock is 139.374% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -0.995, suggesting its less volatile than the S&P 500 by 199.535%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $321.1M. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 13.20x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tango Therapeutics, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of 29.52%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Tango Therapeutics, Inc.'s return on equity of -50.42%.

Kodiak Sciences, Inc. has a consensus price target of $56.33, signalling upside risk potential of 38.65%. On the other hand Tango Therapeutics, Inc. has an analysts' consensus of $21.40 which suggests that it could fall by -5.48%. Given that Kodiak Sciences, Inc. has higher upside potential than Tango Therapeutics, Inc., analysts believe Kodiak Sciences, Inc. is more attractive than Tango Therapeutics, Inc..

Kodiak Sciences, Inc. has a beta of 2.394, which suggesting that the stock is 139.374% more volatile than S&P 500. In comparison Tango Therapeutics, Inc. has a beta of 1.310, suggesting its more volatile than the S&P 500 by 30.959%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tango Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Tango Therapeutics, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Tango Therapeutics, Inc. quarterly revenues of --. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Tango Therapeutics, Inc.'s net income of -$38.7M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Tango Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 40.94x for Tango Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.